European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application
Valneva (VALN) stock surges after EMA validates MAA for Lyme disease vaccine candidate developed with Pfizer (PFE). Phase 3 trial showed efficacy and no safety concerns, pending regulatory approval.
Pfizer and Valneva's new Lyme disease vaccine passed an important safety check from European regulators, which means they're one step closer to selling it. This is good news for both companies because it shows their medicine works and is safe, so watch for updates on whether regulators officially approve it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.